4. Winner: Baxter

Company: Baxter International
Symbol: $BAX
Beginning price: $50.54
Ending price: $68.81
Gain: 36.15%

Baxter International ($BAX) has had issues with infusion pumps, but its drug business--which accounts for about half its revenues--remains solid. It also had about $3 billion in cash sitting on its balance sheet in September, Bloomberg reported. Its share price spiked even higher recently after a rumor surfaced that it was about to spend $4 billion to buy Gambro, one of its key competitors in the kidney dialysis business. If approved, it would round out Baxter's offerings, allow it to cut some costs and remove a competitor from the market.

For more:
Baxter posts Q3 growth, but device sales slide
Report: Baxter close to paying $4B for dialysis rival Gambro
 

4. Winner: Baxter
Read more on

Suggested Articles

Combined with Avastin, Roche's IO med beat Bayer's standard-of-care Nexavar at stalling liver cancer progression—and helped patients live longer, too.

Alexion's campaign to switch patients from blockbuster Soliris to a follow-up drug has gone according to plan. A new indication will help even more.

Sanofi, maker of branded Zantac, is now voluntarily recalling the antacid but has not yet said to what level.